341 related articles for article (PubMed ID: 11682446)
21. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.
Barnette MS; Christensen SB; Essayan DM; Grous M; Prabhakar U; Rush JA; Kagey-Sobotka A; Torphy TJ
J Pharmacol Exp Ther; 1998 Jan; 284(1):420-6. PubMed ID: 9435206
[TBL] [Abstract][Full Text] [Related]
22. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
23. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
Souza DG; Esser D; Bradford R; Vieira AT; Teixeira MM
Br J Pharmacol; 2005 Aug; 145(8):1027-34. PubMed ID: 15951831
[TBL] [Abstract][Full Text] [Related]
24. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Harada D; Tsukumo Y; Takashima Y; Manabe H
Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR
Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266
[TBL] [Abstract][Full Text] [Related]
27. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
28. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
29. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
30. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4.
Brown DM; Hutchison L; Donaldson K; MacKenzie SJ; Dick CA; Stone V
Toxicol Lett; 2007 Jan; 168(1):1-6. PubMed ID: 17129690
[TBL] [Abstract][Full Text] [Related]
31. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
32. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
33. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
34. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
35. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
[TBL] [Abstract][Full Text] [Related]
36. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Spond J; Chapman R; Fine J; Jones H; Kreutner W; Kung TT; Minnicozzi M
Pulm Pharmacol Ther; 2001; 14(2):157-64. PubMed ID: 11273798
[TBL] [Abstract][Full Text] [Related]
37. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
38. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
Kyoi T; Kitazawa S; Tajima K; Zhang X; Ukai Y
J Pharmacol Sci; 2004 Jul; 95(3):321-8. PubMed ID: 15272207
[TBL] [Abstract][Full Text] [Related]
40. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
